Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma

NCT03961698 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer
Renal Cell Carcinoma

Interventions

DRUG: IPI-549 (eganelisib)
DRUG: Atezolizumab
DRUG: nab-paclitaxel
DRUG: Bevacizumab

Sponsor

Infinity Pharmaceuticals, Inc.

Collaborators

[object Object]